Cargando…

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

Anticoagulant plasma concentrations and patient characteristics might affect the benefit–risk balance of therapy. The study objective was to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving rivaroxaban for venous thromboembolism...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinecke, Isabel, Solms, Alexander, Willmann, Stefan, Spiro, Theodore E., Peters, Gary, Weitz, Jeffrey I., Mueck, Wolfgang, Garmann, Dirk, Schmidt, Stephan, Zhang, Liping, Fox, Keith A. A., Berkowitz, Scott D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293976/ https://www.ncbi.nlm.nih.gov/pubmed/32323190 http://dx.doi.org/10.1007/s11239-020-02078-8

Ejemplares similares

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism
por: Solms, Alexander, et al.
Publicado: (2020)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome
por: Zhang, Liping, et al.
Publicado: (2019)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
por: Zhang, Liping, et al.
Publicado: (2020)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
por: Levitan, Bennett, et al.
Publicado: (2014)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022)

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
por: Borris, Lars Carl
Publicado: (2008)

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
por: Du, Wei, et al.
Publicado: (2015)

Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report
por: Rozi, Waail, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study
por: Demelo-Rodríguez, Pablo, et al.
Publicado: (2019)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients
por: Carlin, Stephanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0t43mhuvo3dll7u7d8npot6t1p